IN2014DN09554A - - Google Patents
Info
- Publication number
- IN2014DN09554A IN2014DN09554A IN9554DEN2014A IN2014DN09554A IN 2014DN09554 A IN2014DN09554 A IN 2014DN09554A IN 9554DEN2014 A IN9554DEN2014 A IN 9554DEN2014A IN 2014DN09554 A IN2014DN09554 A IN 2014DN09554A
- Authority
- IN
- India
- Prior art keywords
- cyclohexyl
- pharmaceutical compositions
- relates
- present
- diabetes
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- HPGJSAAUJGAMLV-UHFFFAOYSA-N 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid Chemical compound C1CC(OCCC)CCC1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-UHFFFAOYSA-N 0.000 abstract 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 1
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 229940127003 anti-diabetic drug Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 abstract 1
- 229960004034 sitagliptin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising {2- [3- cyclohexyl -3 (trans- 4- propoxy- cyclohexyl)- ureido]- thiazol- 5- ylsulfanyl}- acetic acid (FRI- 1) in combination with an anti- diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648110P | 2012-05-17 | 2012-05-17 | |
| PCT/US2013/041076 WO2013173417A2 (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09554A true IN2014DN09554A (en) | 2015-07-17 |
Family
ID=48576527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9554DEN2014 IN2014DN09554A (en) | 2012-05-17 | 2013-05-15 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10004782B2 (en) |
| EP (1) | EP2849776B1 (en) |
| JP (1) | JP6234443B2 (en) |
| KR (2) | KR20150013838A (en) |
| CN (2) | CN118453592A (en) |
| AU (2) | AU2013262895A1 (en) |
| BR (1) | BR112014028622A2 (en) |
| CA (1) | CA2872021C (en) |
| EA (1) | EA201492109A1 (en) |
| ES (1) | ES2878001T3 (en) |
| HK (1) | HK1202458A1 (en) |
| IL (1) | IL235484A0 (en) |
| IN (1) | IN2014DN09554A (en) |
| MX (1) | MX360304B (en) |
| SG (2) | SG10201609644UA (en) |
| WO (1) | WO2013173417A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ603614A (en) | 2010-05-26 | 2014-10-31 | Transtech Pharma Llc | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| CN118453592A (en) | 2012-05-17 | 2024-08-09 | Vtv治疗有限责任公司 | Glucokinase activator composition for treating diabetes |
| KR102408480B1 (en) | 2018-05-30 | 2022-06-10 | 이삼구 | Composition for treating diabetic disease |
| LT3804714T (en) * | 2018-05-31 | 2025-03-10 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof |
| AU2019287437A1 (en) * | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| WO2021151251A1 (en) * | 2020-01-31 | 2021-08-05 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| AU2020451588A1 (en) * | 2020-06-04 | 2023-01-19 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CA3185834A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CN116194442A (en) * | 2020-06-08 | 2023-05-30 | 维特卫治疗有限责任公司 | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| CN121202809A (en) * | 2020-06-08 | 2025-12-26 | 维特卫治疗有限责任公司 | Crystalline forms and uses of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazolyl-5-ylthioalkyl}-acetic acid |
| CN115350268B (en) * | 2022-08-24 | 2025-02-11 | 深圳青澜生物技术有限公司 | A preparation for treating diabetes, microneedle and preparation process thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (en) | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | PROCESS FOR PREPARING NEW SALT FROM BIGUANIDS |
| FR2243684B1 (en) | 1973-09-19 | 1977-01-28 | Semb | |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| US6660716B1 (en) * | 1999-06-21 | 2003-12-09 | Eli Lilly And Company | Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| MXPA05009059A (en) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Heteroarylcarbamoylbenzene derivative. |
| WO2005006614A1 (en) * | 2003-07-14 | 2005-01-20 | Sony Corporation | Information providing method |
| WO2005023766A1 (en) | 2003-09-11 | 2005-03-17 | Biocon Limited | Salt of atorvastatin with metformin |
| CN1910166B (en) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | Heteroaryl ureas and their use as glucokinase activators |
| PT1723128E (en) | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaryl-ureas and their use as glucokinase activators |
| JP2008502658A (en) * | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | Use of liver-selective glucokinase activator |
| US20060246141A1 (en) | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| JP2009500378A (en) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | Dicycloalkylcarbamoylureas as glucokinase activators |
| CN101258137A (en) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | Dicycloalkylurea Glucokinase Activator |
| KR20080024211A (en) | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | Dicycloalkyl Urea Glucokinase Activator |
| BRPI0612996A2 (en) | 2005-07-14 | 2010-12-14 | Novo Nordisk As | urea glucokinase activators |
| JP5419706B2 (en) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | Glucokinase activator |
| US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
| EA018988B1 (en) | 2008-05-16 | 2013-12-30 | Такеда Калифорния, Инк. | Glucokinase activators |
| JP5731196B2 (en) | 2008-07-22 | 2015-06-10 | 株式会社クレハ | Process for producing polyarylene sulfide having a reduced content of terminal halogen groups |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| PL2419097T3 (en) | 2009-04-16 | 2014-02-28 | Taisho Pharmaceutical Co Ltd | Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes |
| KR101190957B1 (en) | 2009-08-25 | 2012-10-15 | 한올바이오파마주식회사 | Metformin caffeic acid salt, preparation thereof, pharmaceutical composition comprising the same and combined formulation comprising the same |
| NZ603614A (en) | 2010-05-26 | 2014-10-31 | Transtech Pharma Llc | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| CN118453592A (en) * | 2012-05-17 | 2024-08-09 | Vtv治疗有限责任公司 | Glucokinase activator composition for treating diabetes |
| AU2014226292B2 (en) | 2013-03-04 | 2018-10-04 | Vtv Therapeutics Llc | Solid compositions comprising a glucokinase activator and methods of making and using the same |
| WO2014137797A2 (en) | 2013-03-04 | 2014-09-12 | Transtech Pharma, Llc | Stable glucokinase activator compositions |
-
2013
- 2013-05-15 CN CN202410499223.0A patent/CN118453592A/en active Pending
- 2013-05-15 EA EA201492109A patent/EA201492109A1/en unknown
- 2013-05-15 ES ES13726933T patent/ES2878001T3/en active Active
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en not_active Ceased
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/en active Active
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 MX MX2014013105A patent/MX360304B/en active IP Right Grant
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 HK HK15103235.2A patent/HK1202458A1/en unknown
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/en not_active Application Discontinuation
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/en not_active Ceased
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/en active Pending
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/en active Active
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
-
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
-
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
-
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
-
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX360304B (en) | 2018-10-29 |
| CA2872021C (en) | 2022-08-16 |
| JP2015517525A (en) | 2015-06-22 |
| JP6234443B2 (en) | 2017-11-22 |
| WO2013173417A3 (en) | 2014-02-20 |
| AU2013262895A1 (en) | 2014-11-13 |
| WO2013173417A2 (en) | 2013-11-21 |
| US10004782B2 (en) | 2018-06-26 |
| CN104349790A (en) | 2015-02-11 |
| MX2014013105A (en) | 2015-04-08 |
| KR20150013838A (en) | 2015-02-05 |
| EP2849776B1 (en) | 2021-04-21 |
| SG11201406987UA (en) | 2014-12-30 |
| SG10201609644UA (en) | 2017-01-27 |
| US20180311314A1 (en) | 2018-11-01 |
| BR112014028622A2 (en) | 2017-06-27 |
| AU2017203835A1 (en) | 2017-06-22 |
| US10588943B2 (en) | 2020-03-17 |
| KR20210027547A (en) | 2021-03-10 |
| KR102371364B1 (en) | 2022-03-07 |
| HK1202458A1 (en) | 2015-10-02 |
| US10980861B2 (en) | 2021-04-20 |
| EP2849776A2 (en) | 2015-03-25 |
| EA201492109A1 (en) | 2015-07-30 |
| US20200138909A1 (en) | 2020-05-07 |
| ES2878001T3 (en) | 2021-11-18 |
| US20140066372A1 (en) | 2014-03-06 |
| AU2017203835B2 (en) | 2018-11-22 |
| IL235484A0 (en) | 2014-12-31 |
| CA2872021A1 (en) | 2013-11-21 |
| CN118453592A (en) | 2024-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360304B (en) | Glucokinase activator compositions for the treatment of diabetes. | |
| BR112013029256A2 (en) | "Pharmaceutical combinations for use in the treatment of patients with type 2 diabetes, treatment method, and uses of lixisenatide and metformin." | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| MX2014015423A (en) | Exendin-4 peptide analogues. | |
| BR112015005972A2 (en) | benzoimidazole carboxylic acid amide type derivatives as apj receptor modulators | |
| BR112015013809A2 (en) | exendin-4 derivatives as glp1 / gip double agonists or glp1 / gip / lucagon trigonals, their use and pharmaceutical composition | |
| EA201892383A1 (en) | COMPOSITION FOR THE TREATMENT OF DIABETES OR DIAZHIRENA, CONTAINING ANALOGUE OF OXYNTHOMODULIN | |
| UA117103C2 (en) | A COMPOUND THAT Glucagon agonist activity has | |
| MX2013013307A (en) | Lixisenatide and metformin for treatment of diabetes type 2. | |
| CL2015001241A1 (en) | Use of interleukin 2 (il-2) to treat inflammatory or autoimmune-related disorders (div. Sol. No. 2608-13) | |
| EA201490004A1 (en) | BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES | |
| MY167234A (en) | Novel glucagon analogues | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| BR112014016810A2 (en) | compositions and methods for treating metabolic disorders | |
| EA201490377A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKVINIMODE AND GLATIRAMER ACETATE | |
| UA113849C2 (en) | THE APPLICATION OF SIGMA LIGANDS IN TYPE 2 PATIENTS WITH PAIN | |
| EA201201617A1 (en) | APPLICATION OF METMORPHINE IN COMBINATION WITH GLUCOKINASE ACTIVATOR AND COMPOSITIONS CONTAINING METMORPHIN AND GLUCOKINASE ACTIVATOR | |
| MY165122A (en) | Dipeptidyl peptidase-iv (dppiv) inhibitory peptide compound, composition containing the same, and production method for the same | |
| JOP20130256B1 (en) | Sulfamoyl arylamides and their use as therapeutic agents for the treatment of hepatitis B type | |
| JP2017502074A5 (en) | ||
| MX2016007989A (en) | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of ampk-related diseases. | |
| EA201791611A1 (en) | TREATMENT OF CHILDREN'S PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH LIKSENENIDA | |
| MX2020001434A (en) | Novel acylated insulin analogues and uses thereof. | |
| IN2013MU03847A (en) | ||
| SG10201908089VA (en) | Novel dosing regimens of celgosivir for the treatment of dengue |